The research, published in the journal EMBO Molecular Medicine, presents a promising alternative for the treatment of celiac disease. Currently, the only option for patients is to follow a strict gluten-free diet, as there are no drugs that neutralize the effects of this protein in the body.

The molecule was designed based on neprosin, a natural substance found in a carnivorous plant. According to the researchers, celiacase stands out for its high stability in extreme acidity conditions, such as those found in the human stomach, allowing it to break down toxic gluten fragments before they trigger the inflammatory response characteristic of the disease.

Tests conducted on animal models have shown that the molecule is effective even at very low doses. The results indicate that celiacase could act as an adjuvant treatment, facilitating disease management for people who consume gluten accidentally or in large quantities.

The project has already been protected by a patent, and the research team is working on creating a spin-off company to move toward the next stages of clinical development.